237 filings
Page 3 of 12
6-K
7s9i965xqaz
4 Jan 23
Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol
8:11am
6-K
9w6qdg
14 Dec 22
Current report (foreign)
5:08pm
6-K
nz47p17 i5wdb
16 Nov 22
Current report (foreign)
5:00pm
6-K
faf9s
4 Aug 22
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
8:00am
6-K
cdp926x7mp3kkru
7 Jul 22
Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model
8:47am
424B5
qfg1w 5hwee1
1 Jul 22
Prospectus supplement for primary offering
4:30pm
6-K
198h ns2b
29 Jun 22
Current report (foreign)
4:30pm
6-K
f29dxrkx6ohknpyj1vj
22 Jun 22
Current report (foreign)
5:00pm
6-K
wgx9c60u8ei
17 Jun 22
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
4:15pm
6-K
kl7853mkid3vtbi4346
17 May 22
Current report (foreign)
9:08am
6-K
fgnnmxcqdci9n6auiohe
17 May 22
Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results
8:20am
6-K
6ra4kmq7
17 May 22
Galmed updates business and clinical development strategy to better leverage Aramchol’s anti-fibrotic effects
7:51am
6-K
yzjkahpvuq1u3b7zi2
2 May 22
Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial
7:07am
6-K
94jdfxy1
28 Apr 22
Current report (foreign)
8:04am
6-K
vzac7
3 Mar 22
Current report (foreign)
5:16pm
6-K
khx 1p7vrp6mfi2u
11 Jan 22
Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt
8:15am
6-K
hdmunwxjrx
10 Jan 22
Galmed announces positive results of Phase 1 study of Amilo-5MER
8:11am
6-K
052r0
8 Nov 21
Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results
8:25am
6-K
8kdpbob7 9zzztr
1 Nov 21
Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study
10:23am